identifying predictors for ruxolitinib treatment-related thrombocytopenia in patients with mf
Published 10 months ago • 127 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
1:44
predicting thrombocytopenia as a result of ruxolitinib treatment in mf
-
1:05
hematological predictors of thrombotic risk or disease progression in essential thrombocythemia
-
2:41
bomedemstat combined with ruxolitinib for the treatment of mf: early results of a phase ii trial
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
1:17
the use of pacritinib in thrombocytopenic patients with myelofibrosis undergoing allosct
-
0:52
insights from advance iv study: efgartigimod increases platelet counts of patients with itp
-
1:05
using whole genome sequencing to identify novel predictors for sct in patients with mds
-
0:52
the role and clinical use of tpo receptor agonists in the treatment of itp
-
1:40:08
hemepath & hematology board review: peripheral blood smears with dr. jeanette ramos
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
4:44
7-year update on a phase ii trial of fixed-duration obinutuzumab, ibrutinib, and venetoclax for cll
-
1:17
diagnosing rt and identifying patients at risk using ngs and molecular cytogenetic analysis
-
1:43
the role of complement activation in complications of sickle cell disease
-
3:17
thrombopoietin receptor agonists in itp: current status and future outlooks
-
4:13
real-world study determining the safety and efficacy of teclistamab in r/r multiple myeloma
-
2:45
continuity of care for patients with hematological predispositions to aml
-
1:39
scd: assessing bleeding severity in thrombocytopenic patients
-
1:11
genomic testing can help identify patient risk factors and guide clinical decision-making
-
1:06
overview of the diagnostic work-up for hemophilia
-
2:13
nursing track: pharmacy updates
-
3:47
a new form of inherited thrombocytopenia: etv6, never judge a book by its cover
-
1:07
identifying operational tolerance pathways after sct & cgvhd immune profiles with machine learning